

March 11, 2020

Guidance to Researchers Regarding Determination of "Essential to the health and/or well-being" for human subject research visits during the COVID-19 outbreak.

The [interim UCSF policy](#) on human subject research visits at UCSF's San Francisco campuses during the COVID-19 outbreak requires determination of whether or not a research visit is "essential to the health and/or well-being of a participant." **The following examples are provided as a guide to help principal investigators, participants, and participant care providers determine suitability of in-person research visits. These determinations and the balance of potential benefits and harms will vary by study objectives, target patient population, and may change as the COVID-19 outbreak evolves.** The following examples are not intended to be comprehensive of all study types.

- Please send questions about this guidance or UCSF's interim policy to research@ucsf.edu.
- Please send questions about coronavirus to emer.mgt@ucsf.edu.

| For these study designs: | Is the specific research visit " <u>essential to the health and/or well-being</u> " of the participant, thus supporting in-person visits? | | |
|--|---|--|---|
| | These visit types are LIKELY "essential" (supports an in-person visit) | These visit types may or may not be "essential" (Support for in-person visit will depend on specifics of the study) | These visit types are LIKELY not "essential" (does not support an in-person visit) |
| Randomized controlled efficacy trial (e.g., phase IIb or III) of a potential drug or device or other intervention | <ul style="list-style-type: none"> • New enrollments • Follow ups | | |
| Post-approval trial (e.g., phase IV) of a therapeutic drug, device, or other intervention to assess tolerability and/or long-term benefit | <ul style="list-style-type: none"> • Follow ups | <ul style="list-style-type: none"> • New enrollments | |
| Early phase (e.g., phase I or IIa) pharmacodynamic, safety, tolerability or feasibility trial a potential drug or device or other intervention | <ul style="list-style-type: none"> • Follow ups | <ul style="list-style-type: none"> • New enrollments | |
| Non-randomized interventional trial of a drug, device, or other intervention requiring safety monitoring | <ul style="list-style-type: none"> • Follow ups | <ul style="list-style-type: none"> • New enrollments | |
| Non-randomized interventional trial of a drug, device, or other intervention not requiring safety monitoring | | <ul style="list-style-type: none"> • New enrollments • Follow ups | |
| Comparative effectiveness studies or other study types describing the natural history of disease or other clinical outcomes | | <ul style="list-style-type: none"> • Follow ups | <ul style="list-style-type: none"> • New enrollments |
| Non-interventional qualitative study | | | <ul style="list-style-type: none"> • New enrollments • Follow ups |
| Non-interventional study with collection of clinical data and/or biological specimens for future research | | | <ul style="list-style-type: none"> • New enrollments • Follow ups |